Strategic Asset Sales Nabriva recently completed asset divestitures, including the sale of Contepo North American rights to Meitheal Pharmaceuticals in July 2024 and prior asset sales to Sumitomo Pharma in 2023. This indicates a potential for partnerships or licenses to access remaining assets or pipeline products, and suggests buyers view certain assets as strategic exits.

Expanded Clinical Portfolio The company has two marketed products, Xenleta and Contepo, with ongoing NDA activities for Contepo in the U.S. for cUTI. This presents cross-sell potential to institutions already using Xenleta, as well as opportunities to expand antibacterial coverage through Contepo approvals and channel expansion in North America via partners.

Geographic Footprint With headquarters in Ireland and operations in the U.S. and Austria, Nabriva maintains a multi-region presence. This geographic spread offers business development opportunities for regional distributors, co-promotion arrangements, or joint ventures that leverage local market access and regulatory familiarity.

Clinical Development Opportunity Contepo’s NDA activity and Xenleta’s existing market presence create a pathway for BD discussions around pipeline expansion, exclusive licensing, or collaboration on next-generation anti-infectives. Engaging for potential co-development or milestone-based deals could accelerate market reach.

Financial and Partnering Signals Recent asset divestitures may reflect a strategic shift toward monetizing mature assets and focusing on core offerings. This can signal openness to strategic partnerships, equity investments, or licensing deals with favorable terms for buyers seeking exposure to anti-infectives in a commercial-stage biotech.